Abstract
Short-term results after kidney transplantation have dramatically improved over the last decade. The introduction of new drugs such as cyclosporin (CsA) has decreased the incidence of acute rejection episodes and, consequently, the proportion of grafts lost during the first year after transplantation [1]. However, longterm results have not reflected the same progress since, in most registries, the yearly rate of grafts lost beyond the first year has remained unchanged [2].
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Canadian Multicenter Transplant Study Group. A randomized clinical trial of cyclosporin in cadaveric renal transplantation. N. Engl. J. Med. 1983; 309: 809–813.
Schweitzer EJ, Matas AJ, Gillingham KJ et al. Causes of renal allograft loss. Ann. Surg. 1991; 214: 679–688.
Cecka JM, Gjertson D, Terasaki PI. Do prophylactic antilymphocyte globulins (ALG and OKT3) improve renal transplant survival in recipient and donor high-risk groups? Transplant. Proc. 1993; 25: 548.
Griñó JM, Alsina J, Sabater R et al. Antilymphoblast globulin, cyclosporin and steroids in cadaveric renal transplantation. Transplantation 1990; 49: 1114–1117.
Stratta RJ, D’Alessandro AM, Armbrust MJ et al. Sequential antilymphocyte globulin/cyclosporin immunosuppression in cadaveric renal transplantation. Transplantation 1989; 47: 96–102.
Norman DJ, Kahana L, Stuart FP Jr et al. A randomized clinical trial of induction therapy with OKT3 in kidney transplantation. Transplantation 1993; 55: 44–50.
Grinyo JM, Castelao AM, Serón D et al. Antilymphocyte globulin versus OKT3 induction therapy in cadaveric kidney transplantation: a prospective randomized study. Am. J. Kidney Dis. 1992; 20: 603–610.
Grinyo JM. Early immunosuppression in renal transplantation. J. Nephrol. 1994; 7: 148–157.
Najarian JS, Gillingham KJ, Sutherland DER, Reinsmoen NL, Payne WD, Matas AJ. The impact of the quality of initial graft function on cadaver kidney transplants. Transplantation 1994; 57: 812–816.
Matas AJ, Gillingham KJ, Payne WD, Najarian JS. The impact of an acute rejection episode on long-term renal allograft survival (t1/2). Transplantation 1994; 57: 857–859.
Yilmaz S, Häyry P. The impact of acute episodes of rejection on the generation of chronic rejection in rat renal allografts. Transplantation 1993; 56: 1153–1156.
Almond PS, Matas A, Gillingham K et al. Risk factors for chronic rejection in renal allograft recipients. Transplantation 1993; 55: 752–757.
Abramowicz D, Norman DJ, Vereerstraeten P et al. OKT3 prophylaxis in renal grafts with prolonged cold ischemia times: association with improvement in long-term survival. Kidney Int. 1996; 49: 768–772.
Brenner BM, Milford L. Nephron underdosing: a programmed cause of chronic renal allograft failure. Am. J. Kidney 1993; 21: 66–72.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1997 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Alsina, J. et al. (1997). Longterm allograft outcome in patients treated with prophylactic antilymphocyte globulin or OKT3 as induction therapy in cadaveric kidney transplantation. In: Touraine, J.L., Traeger, J., Bétuel, H., Dubernard, J.M., Revillard, J.P., Dupuy, C. (eds) Late Graft Loss. Transplantation and Clinical Immunology, vol 28. Springer, Dordrecht. https://doi.org/10.1007/978-94-011-5434-5_15
Download citation
DOI: https://doi.org/10.1007/978-94-011-5434-5_15
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-010-6286-2
Online ISBN: 978-94-011-5434-5
eBook Packages: Springer Book Archive